预测肝细胞癌免疫治疗的预后
Biomarkers of Immunotherapy for Hepatocellular Carcinoma
DOI: 10.12677/ACM.2023.13122629, PDF,   
作者: 王奇峰：青海大学研究生院，青海 西宁；王海久*：青海大学附属医院普外二科，青海 西宁
关键词: 肝细胞癌；免疫疗法；联合疗法；生物标志物；Hepatocellular Carcinoma； Immunotherapy； Combination Therapy； Biomarkers
摘要: 肝细胞癌(Hepatocellular carcinoma, HCC)是世界上最常见的肝癌，也是癌症死亡相关的主要原因之一。目前临床上单免疫治疗和免疫检查点抑制剂(Immune checkpoint inhibitors, ICIs)和多靶点酪氨酸激酶抑制剂(Tyrosine kinase inhibitors, TKIs)或抗血管内皮生长因子(Vascular endothelial growth factor, VEGF)抑制剂的联合治疗已成为晚期肝细胞癌(aHCC)的新标准疗法。然而，这些治疗的临床益处仍然有限。因此，迫切需要适当的生物标志物来预测对免疫疗法的治疗反应，以最大限度提高临床益处，同时避免不必要的毒性反应。截止到目前，还没有公认的生物标志物可用于预测HCC患者对免疫治疗的预后。因此，本文综述了肝细胞癌生物标志物的预测和预后，以期为HCC生物标志物探索和临床治疗选择的研究指导方向。
Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer in the world and one of the leading causes of cancer-related death. Currently, single immunotherapy, Immune checkpoint inhibitors (ICIs), and multi-target Tyrosine kinase inhibitors are clinically recognized. Combination therapy with TKIs or anti-vascular endothelial growth factor (VEGF) inhibitors has become the new standard of treatment for advanced hepatocellular carcinoma (aHCC). However, the clinical benefits of these treatments are still limited. Therefore, there is an urgent need for appropriate biomarkers to pre-dict therapeutic responses to immunotherapy to maximize clinical benefit while avoiding unneces-sary toxic reactions. To date, there are no recognized biomarkers that can be used to predict the prognosis of HCC patients in response to immunotherapy. Therefore, this review reviews the predic-tion and prognosis of biomarkers for hepatocellular carcinoma, with a view to guiding the research direction of biomarker exploration and clinical treatment selection for HCC.
文章引用：王奇峰, 王海久. 预测肝细胞癌免疫治疗的预后[J]. 临床医学进展, 2023, 13(12): 18703-18708. https://doi.org/10.12677/ACM.2023.13122629

参考文献

[1] Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcino-ma. Nature Reviews Disease Primers, 7, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[2] Roayaie, S., Obeidat, K., Sposito, C., Mariani, L., Bhoori, S., Pellegrinelli, A., et al. (2013) Resection of Hepatocellular Cancer ≤ 2cm: Results from Two Western Centers. Hepatology, 57, 1426-1435. [Google Scholar] [CrossRef] [PubMed]
[3] Zhu, A.X., Finn, R.S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., et al. (2018) Pembrolizumab in Patients with Ad-vanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open- La-bel Phase 2 Trial. The Lancet Oncology, 19, 940-952.
[4] El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef] 
[5] Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R. and Mantovani, A. (2020) Neutrophil Diversity and Plasticity in Tumour Progression and Therapy. Nature Reviews Cancer, 20, 485-503. [Google Scholar] [CrossRef] [PubMed]
[6] Jensen, H.K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F. and von der Maase, H. (2009) Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. Journal of Clinical Oncology, 27, 4709-4717. [Google Scholar] [CrossRef] 
[7] Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., et al. (2016) Derived Neutrophil Lymphocyte Ratio Is Predictive of Survival from Intermittent Therapy in Advanced Colorectal Cancer: A Post Hoc Analysis of the MRC COIN Study. British Journal of Cancer, 114, 612-615. [Google Scholar] [CrossRef] [PubMed]
[8] Gu, X., Gao, X., Li, X., Qi, X., Ma, M., Qin, S., et al. (2016) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: Evidence from 16, 266 Patients. Scientific Reports, 6, Article No. 22089. [Google Scholar] [CrossRef] [PubMed]
[9] Lin, G., Liu, Y., Li, S., Mao, Y., Wang, J., Shuang, Z., et al. (2016) Ele-vated Neutrophil-to-Lymphocyte Ratio Is an Independent Poor Prognostic Factor in Patients with Intrahepatic Cholangi-ocarcinoma. Oncotarget, 7, 50963-50971. [Google Scholar] [CrossRef] [PubMed]
[10] Sun, H.L., Pan, Y.Q., He, B.S., Nie, Z.L., Lin, K., Peng, H.X., et al. (2016) Prognostic Performance of Lymphocyte-to-Monocyte Ratio in Diffuse Large B-Cell Lymphoma: An Updated Meta-Analysis of Eleven Reports. OncoTargets and Therapy, 9, 3017-3023. [Google Scholar] [CrossRef] 
[11] Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., et al. (2017) Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Pa-tients with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer, 111, 176-181. [Google Scholar] [CrossRef] [PubMed]
[12] Guo, L., Ren, H., Pu, L., Zhu, X., Liu, Y. and Ma, X. (2020) The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study. Cancer Management and Research, 12, 7173-7188. [Google Scholar] [CrossRef] 
[13] Sangro, B., Melero, I., Wadhawan, S., Finn, R.S., Abou-Alfa, G.K., Cheng, A.L., et al. (2020) Association of Inflammatory Biomarkers with Clinical Outcomes in Nivolumab-Treated Pa-tients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 73, 1460-1469. [Google Scholar] [CrossRef] [PubMed]
[14] Choi, W.M., Kim, J.Y., Choi, J., Lee, D., Shim, J.H., Lim, Y.S., et al. (2021) Kinetics of the Neutrophil-Lymphocyte Ratio during PD-1 Inhibition as a Prognostic Factor in Advanced Hepatocellular Carcinoma. Liver International, 41, 2189-2199. [Google Scholar] [CrossRef] [PubMed]
[15] Muhammed, A., Fulgenzi, C.A.M., Dharmapuri, S., Pinter, M., Balcar, L., Scheiner, B., et al. (2021) The Systemic Inflammatory Re-sponse Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers, 14, Article 186. [Google Scholar] [CrossRef] [PubMed]
[16] Waugh, D.J. and Wilson, C. (2008) The Interleu-kin-8 Pathway in Cancer. Clinical Cancer Research, 14, 6735-6741. [Google Scholar] [CrossRef] 
[17] Motomura, T., Shirabe, K., Mano, Y., Muto, J., Toshima, T., Umemoto, Y., et al. (2013) Neutrophil-Lymphocyte Ratio Reflects Hepatocellular Carcinoma Recurrence after Liver Transplantation via Inflammatory Microenvironment. Journal of Hepatology, 58, 58-64. [Google Scholar] [CrossRef] [PubMed]
[18] Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.F., et al. (2017) Histological Subtypes of Hepatocellular Carcinoma Are Related to Gene Mutations and Molec-ular Tumour Classification. Journal of Hepatology, 67, 727-738. [Google Scholar] [CrossRef] [PubMed]
[19] Chan, S.L., Mo, F.K., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., et al. (2009) New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients with Hepatocellular Carcinoma Undergoing Systemic Chemotherapy. Journal of Clinical On-cology, 27, 446-452. [Google Scholar] [CrossRef] 
[20] Vora, S.R., Zheng, H., Stadler, Z.K., Fuchs, C.S. and Zhu, A.X. (2009) Serum α-Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma. Oncologist, 14, 717-725. [Google Scholar] [CrossRef] [PubMed]
[21] Shao, Y.Y., Lin, Z.Z., Hsu, C., Shen, Y.C., Hsu, C.H. and Cheng, A.L. (2010) Early α-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma. Cancer, 116, 4590-4596. [Google Scholar] [CrossRef] [PubMed]
[22] Hu, X., Chen, R., Wei, Q. and Xu, X. (2022) The Landscape of α Feto-protein in Hepatocellular Carcinoma: Where Are We? International Journal of Biological Sciences, 18, 536-551. [Google Scholar] [CrossRef] [PubMed]
[23] Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B.P., Horger, M., et al. (2020) Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers, 12, Article 3830. [Google Scholar] [CrossRef] [PubMed]
[24] Scheiner, B., Pomej, K., Kirstein, M.M., Hucke, F., Finkelmeier, F., Waidmann, O., et al. (2022) Prognosis of Patients with Hepatocellular Carcinoma Treated with Immunothera-py—Development and Validation of the CRAFITY Score. Journal of Hepatology, 76, 353-363. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, Y., Ouyang, J., Zhou, Y., Zhou, J. and Zhao, H. (2022) The CRAFITY Score: A Promising Prognostic Predictor for Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitor and Immunotherapy Combinations. Journal of Hepatology, 77, 574-576. [Google Scholar] [CrossRef] [PubMed]
[26] Chen, J., Zaidi, S., Rao, S., Chen, J.S., Phan, L., Farci, P., et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expres-sion Changes in the Transforming Growth Factor-β Pathway. Gastroenterology, 154, 195-210. [Google Scholar] [CrossRef] [PubMed]
[27] Chen, J., Gingold, J.A. and Su, X. (2019) Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends in Molecular Medicine, 25, 1010-1023. [Google Scholar] [CrossRef] [PubMed]
[28] Rebouissou, S. and Nault, J.C. (2020) Advances in Molecular Classification and Precision Oncology in Hepatocellular Carcinoma. Journal of Hepatology, 72, 215-229. [Google Scholar] [CrossRef] [PubMed]
[29] Park, B.V., Freeman, Z.T., Ghasemzadeh, A., Chattergoon, M.A., Rutebemberwa, A., Steigner, J., et al. (2016) TGFβ1- Mediated SMAD3 Enhances PD-1 Expression on Anti-gen-Specific T Cells in Cancer. Cancer Discovery, 6, 1366-1381. [Google Scholar] [CrossRef] 
[30] Chen, J. and Su, X. (2020) Abstract 4286: TGF-β Signature Is a Therapeutic Biomarker for Combination Immunotherapy for Hepatocellular Carcinoma. Cancer Research, 80, 4286. [Google Scholar] [CrossRef] 
[31] Feun, L.G., Li, Y.Y., Wu, C., Wangpaichitr, M., Jones, P.D., Richman, S.P., et al. (2019) Phase 2 Study of Pembrolizumab and Circulating Biomarkers to Predict Anticancer Response in Advanced, Unresectable Hepatocellular Carcinoma. Cancer, 125, 3603-3614. [Google Scholar] [CrossRef] [PubMed]
[32] Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548. [Google Scholar] [CrossRef] [PubMed]
[33] Cheuk, A.T., Mufti, G.J. and Guinn, B.A. (2004) Role of 4-1BB:4-1BB Ligand in Cancer Immunotherapy. Cancer Gene Therapy, 11, 215-226. [Google Scholar] [CrossRef] [PubMed]
[34] Reithofer, M., Rosskopf, S., Leitner, J., Battin, C., Bohle, B., Stein-berger, P., et al. (2021) 4-1BB Costimulation Promotes Bystander Activation of Human CD8 T Cells. European Journal of Immunology, 51, 721-733.
[35] Heinisch, I.V., Daigle, I., Knöpfli, B. and Simon, H.U. (2000) CD137 Activation Abrogates Granulocyte-Macrophage Colony-Stimulating Factor-Mediated Anti-Apoptosis in Neutrophils. European Journal of Immunology, 30, 3441-3446. [Google Scholar] [CrossRef] 
[36] Kim, H.D., Park, S., Jeong, S., Lee, Y.J., Lee, H., Kim, C.G., et al. (2020) 4-1BB Delineates Distinct Activation Status of Exhausted Tu-mor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, 71, 955-971. [Google Scholar] [CrossRef] [PubMed]
[37] Michel, J., Langstein, J., Hofstädter, F. and Schwarz, H. (1998) A Soluble form of CD137 (ILA/4-1BB), a Member of the TNF Receptor Family, Is Released by Activated Lymphocytes and Is Detectable in Sera of Patients with Rheumatoid Arthritis. European Journal of Immunology, 28, 290-295. [Google Scholar] [CrossRef] 
[38] Vinay, D.S. and Kwon, B.S. (1998) Role of 4-1BB in Immune Responses. Seminars in Immunology, 10, 481-489. [Google Scholar] [CrossRef] [PubMed]
[39] Geuijen, C., Tacken, P., Wang, L.C., Klooster, R., van Loo, P.F., Zhou, J., et al. (2021) A Human CD137×PD-L1 Bispecific Antibody Promotes Anti-Tumor Immunity via Con-text-Dependent T Cell Costimulation and Checkpoint Blockade. Nature Communications, 12, Article No. 4445. [Google Scholar] [CrossRef] [PubMed]
[40] Jacquelot, N., Roberti, M.P., Enot, D.P., Rusakiewicz, S., Ternès, N., Jegou, S., et al. (2017) Predictors of Responses to Immune Checkpoint Blockade in Advanced Melanoma. Nature Communications, 8, Article 592.
[41] Zhang, W., Gong, C., Peng, X., Bi, X., Sun, Y., Zhou, J., et al. (2022) Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevaci-zumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research, 28, 3499-3508. [Google Scholar] [CrossRef] 

为你推荐